ABCL
Abcellera Biologics Inc
12.50$
+4.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.1% | 81.1% | 80.6% | 103.3% | 88.4% | 81.4% | 80.1% | 17.2% | 9.9% | 13.1% | 316.8% | 15.7% | 14.1% | 11.3% | 14.8% | 7.2% | 431.8% | 72.2% | 112.3% | 99.2% | 68.0% | 519.4% | 588.5% | 275.3% | 1,003.4% | 41.3% | – | 17.7% | 104.1% | – | – | |
| 18.9% | 18.9% | 19.4% | -3.3% | 100.0% | 100.0% | 100.0% | 100.0% | 90.1% | 86.9% | 100.0% | 84.3% | 85.9% | 88.7% | 85.2% | 92.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 82.3% | -4.1% | 100.0% | 75.0% | |
| 81.1% | 81.1% | 80.6% | 103.3% | 88.4% | 81.4% | 80.1% | 4.2% | 6.1% | 54.4% | 316.8% | 12.4% | 8.3% | 58.1% | 26.2% | 131.1% | 431.8% | 362.7% | 574.6% | 529.7% | 394.7% | 558.9% | 629.6% | 912.4% | 1,003.4% | 229.5% | 614.5% | 111.7% | 561.2% | 1,135.5% | 298.9% | |
| 21.6% | 21.6% | 20.4% | 30.4% | 35.4% | 13.3% | 31.7% | 2.8% | 3.2% | 40.5% | 204.6% | 9.3% | 4.5% | 31.4% | 13.6% | 60.4% | 124.1% | 154.3% | 217.7% | 174.0% | 174.3% | 275.7% | 294.3% | 317.2% | 383.1% | 111.1% | 246.3% | 127.7% | 148.3% | 342.0% | 159.4% | |
| 30.9% | 30.9% | 18.2% | 161.7% | 145.6% | 107.6% | 118.9% | 22.7% | 12.2% | 112.4% | 610.1% | 25.8% | 14.8% | 106.9% | 47.9% | 268.1% | 632.1% | 611.0% | 931.8% | 819.6% | 651.5% | 1,376.2% | 1,539.4% | 1,540.7% | 1,579.6% | 390.2% | 951.8% | 146.1% | 687.7% | 1,650.0% | 415.2% | |
| -28.7% | -28.7% | -20.7% | -61.7% | -45.6% | -7.6% | -18.9% | 77.3% | 78.0% | -25.4% | -510.1% | 58.5% | 71.1% | -18.3% | 37.2% | -175.3% | -532.1% | -511.0% | -831.8% | -719.6% | -551.5% | -1,276.2% | -1,439.4% | -1,440.7% | -1,479.6% | -290.2% | -851.8% | -63.7% | -691.7% | -1,550.0% | -340.3% | |
| – | – | – | 2.6% | – | – | – | 0.8% | 0.8% | – | – | 3.8% | 0.2% | 0.1% | 6.6% | 52.9% | 137.2% | – | – | 182.2% | – | – | – | – | 190.1% | – | – | 35.9% | – | 1.0% | – | |
| -12.2% | -12.2% | 1.0% | -51.2% | -44.9% | 59.7% | -28.8% | 75.0% | 79.7% | -7.5% | -453.4% | 60.8% | 72.9% | -15.0% | 46.0% | -145.8% | -394.9% | -377.9% | -595.2% | -529.5% | -429.4% | -658.0% | -962.5% | -927.3% | -1,251.1% | -212.7% | -767.9% | -43.5% | -595.8% | -1,455.9% | -297.4% | |
| – | – | – | 2.6% | – | – | 0.0% | 18.7% | 21.8% | 0.9% | -65.2% | 17.8% | 19.7% | -0.2% | 19.7% | -7.1% | -65.9% | -74.3% | -161.6% | -15.8% | -21.5% | -153.7% | -177.1% | -249.9% | -173.9% | -9.5% | -130.1% | -23.5% | -76.6% | -87.4% | -48.5% | |
| -12.2% | -12.2% | 1.0% | -51.2% | -44.9% | 59.7% | -28.8% | 56.3% | 57.8% | -8.4% | -388.2% | 43.0% | 53.2% | -14.8% | 26.3% | -138.7% | -329.0% | -303.6% | -433.6% | -513.7% | -408.0% | -504.3% | -785.4% | -677.4% | -1,077.2% | -203.3% | -637.8% | -19.9% | -519.1% | -1,368.6% | -248.8% | |
| -12.8% | -12.8% | -9.4% | -33.1% | -9.6% | 71.9% | 5.4% | 77.4% | 81.5% | 6.6% | -354.2% | 67.6% | 74.3% | -1.8% | 46.0% | -21.6% | -446.0% | -393.4% | -676.7% | -583.6% | -450.6% | -711.6% | -797.2% | -1,095.3% | -1,225.5% | -227.3% | -740.5% | -25.8% | -491.7% | -1,025.4% | -242.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.